completed

The objective of the CHARM study was to determine the effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme.

Primary endpoints:

The primary outcome was all-cause death.

The outcomes in the three component trials were:

  • Cardiovascular death or hospitalization for worsening heart failure
  • Cardiovascular death, admission to hospital for CHF, or non-fatal myocardial infarction
  • Cardiovascular death, admission to hospital for CHF, non-fatal myocardial infarction or non-fatal stroke
  • Cardiovascular death, admission to hospital for CHF, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularisation
  • Death (any cause) or admission to hospital for CHF
  • Development of new diabetes.

All outcome events were adjudicated.

Study Type

Interventional - Drug

Study Design

Randomized, double-blind, parallel group design

NO. of Countries

24

NO. of Sites

618

NO. of Participants

7601

Study Period

1999 - 2000

Sponsor

PHRI

Back To Top